Publications: 186 in 2026-04. +0.9% share of all MeSH-indexed PubMed records vs the same month last year (189 in 2025-04).
PublicationsPubMed
1862026-04
+0.9% share of all MeSH-indexed PubMed records vs same month last year (189 in 2025-04)provisional · settling
0.17% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 13 in 2026-09. -35.0% vs the same month last year (20 in 2025-09).
Clinical trialsClinicalTrials.gov
132026-09
-35.0% vs same month last year (20 in 2025-09)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 83 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 83 is in the 97th percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
832026-09
97th percentilenear its historical high, versus 16-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 60 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 60 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
602026-09
78th percentilerunning high, versus 16-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 7 in 2026-09. No percentage shown. No percentage shown: both months are under 15 records. The count is ranked in its own history instead. Preprints: latest count 7 is in the 53rd percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
72026-09
53rd percentilein its typical range, versus 16-mo window (2025 to 2026)low volume
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 186 is in the 62nd percentile, in its typical range, versus 320 months since 2000.
62ndpercentile
in its typical range
186/mo · higher than 61% of 320 months since 2000
Clinical trials
Clinical trials: latest count 13 is in the 50th percentile, in its typical range, versus 314 months since 2000.
50thpercentile
in its typical range
13/mo · higher than 46% of 314 months since 2000
NIH grantsprovisional
NIH grants: latest count 83 is in the 97th percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
97thpercentile
near its historical high
83/mo · higher than 94% of 16-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 60 is in the 78th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
78thpercentile
running high
60/mo · higher than 75% of 16-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 7 is in the 53rd percentile, in its typical range, versus 16-mo window (2025 to 2026) (provisional, short baseline).
53rdpercentile
in its typical range
7/mo · higher than 38% of 16-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 16 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 314 mo; NIH grants 2025 to 2026 · 16 mo; Patents 2025 to 2026 · 16 mo; Preprints 2025 to 2026 · 16 mo.
Publications2000 to 2026 · 320 mopeak 377/mo
Clinical trials2000 to 2026 · 314 mopeak 69/mo
NIH grants2025 to 2026 · 16 mobackfill pendingpeak 83/mo
Patents2025 to 2026 · 16 mobackfill pendingpeak 76/mo
Preprints2025 to 2026 · 16 mobackfill pendingpeak 10/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-08..2026-07
4%of works have an industry affiliation
Memorial Sloan Kettering Cancer Center226
Dana-Farber Cancer Institute211
National and Kapodistrian University of Athens194
Mayo Clinic in Arizona162
The University of Texas MD Anderson Cancer Center161
Clinical trials
Lead sponsors · 2023-10..2026-09
15%industry-led in 2026-09
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic/other32
National Cancer Institute (NCI)NIH24
GlaxoSmithKlineIndustry15
Janssen Research & Development, LLCIndustry13
Mayo ClinicAcademic/other12
NIH grants
Funded institutions · 2025-06..2026-09
577awards in window
DANA-FARBER CANCER INSTMA · $31M · P01/R0149
WASHINGTON UNIVERSITYMO · $16.9M · R01/U2C28
MAYO CLINIC ROCHESTERMN · $11.2M · P30/R0125
UNIVERSITY OF PENNSYLVANIAPA · $24.8M · P01/R0123
FRED HUTCHINSON CANCER CENTERWA · $21.8M · P01/R0123
Patents
Applicants · 2025-06..2026-09
Janssen Biotech, Inc.19
Regeneron Pharmaceuticals, Inc.18
The Regents of the University of California12
BioNTech SE10
Hoffmann-La Roche Inc.9
Preprints
Corresponding institutions · 2025-06..2026-09
University of Pennsylvania3
Center for Cancer Research, NCI, NIH2
City of Hope2
Department of Medicine, National University of Singapore2
2026-09-23biorxivBotnar Research Centre, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, OX3 7LD, UK; Oxford Translational M
2026-09-10biorxivUniversity of California, San Francisco
Organizations only. No person data.
Would you read a monthly digest for Multiple Myeloma?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Multiple Myeloma. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Multiple Myeloma.
How we map "Multiple Myeloma"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Multiple Myeloma"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10
Author institutions (OpenAlex)
topic T10649; search 'multiple myeloma'
Clinical trials (ClinicalTrials.gov)
ConditionSearch: multiple myeloma OR plasma cell myeloma